Abstract 99P
Background
The SUNLIGHT trial demonstrated improved overall survival (OS) by adding bevacizumab (Bev) to trifluridine-tipiracil (FTD-TPI) in patients with metastatic colorectal cancer (mCRC). The prognostic impact of adding Bev has been reported in patients with liver metastases (LM) and KRAS G12 mutation in the SUNLIGHT trial. However, there are few reports on prognostic factors with regards to FTD-TPI plus Bev, particularly whether LM and KRAS G12 mutation are prognostic factors. This study was conducted to investigate clinicopathological factors associated with the prognosis in mCRC patients treated with FTD-TPI plus Bev in the real-world setting.
Methods
Clinical information of patients treated with FTD-TPI plus Bev were collected from the medical records at our institution from October 2017 to November 2023. A multivariate analysis was performed on OS, including the factors of ECOG performance status, sex, age, number of metastatic sites, location of primary site, history of primary site resection, liver metastasis, and KRAS G12 mutation status.
Results
One hundred patients were included to this study, with a median follow-up of 8.56 months. The median age was 59 years (range: 21–84). The proportions of patients with LM or KRAS G12 mutation were 76%, and 32%, respectively. Ninety-seven percent of patients had previously received anti-VEGF therapy. Median progression-free survival (PFS) and OS for all patients were 2.62 months (95% CI: 2.13–3.41) and 9.52 months (95% CI: 7.16–11.1), respectively. A multivariate analysis of OS identified more than three metastatic sites (HR 1.80, [95% CI: 1.10–2.94]; p=0.019) and right-sided tumor location (HR 1.76, [95% CI: 1.04–2.99]; p=0.036) as poor prognostic factors. No significant OS differences were observed for LM (HR 0.85 [95%CI: 0.48–1.49], p=0.576) and KRAS G12 mutation (HR 0.89 [95%CI:0.56–1.44]; p=0.645).
Conclusions
Among the mCRC patients treated with FTD-TPI plus Bev in clinical practice, the number of metastatic sites and the location of primary tumor site are the prognostic factors, while prognostic association of LM and KRAS G12 mutation were unclear.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Center Hospital, Tokyo, Japan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.